Autolus Therapeutics PLC (NAS:AUTL)
$ 3.88 0.04 (1.04%) Market Cap: 1.03 Bil Enterprise Value: 321.04 Mil PE Ratio: 0 PB Ratio: 1.77 GF Score: 55/100

Autolus Therapeutics PLC at JPMorgan Healthcare Conference (Virtual) Transcript

Jan 12, 2022 / 01:15PM GMT
Release Date Price: $4.55 (-4.81%)
Eric William Joseph
JPMorgan Chase & Co, Research Division - VP & Senior Analyst

Good morning, and thanks for joining the 40th Annual JPMorgan Healthcare Conference. I'm Eric Joseph, senior biotech analyst with the firm. And our next presenting company is Autolus. And here to talk to us a little bit about the company is CEO, Christian Itin. There is a Q&A session after the presentation. So just click the icon and I'll work in questions where appropriate. With that, Christian, thanks so much for sharing some of your time with us this week.

Christian Martin Itin
Autolus Therapeutics plc - CEO & Director

Well, thank you very much. Thanks, Eric, for having us at the conference. I'm looking forward to giving you an update on where we are with Autolus and give you an outlook on the activities planned for this year and into next year.

So we're a company focused on the development of CAR T therapies. We're listed on NASDAQ. If you go on Slide 2, please have a look at our SEC filings for a full set of disclosures and also the risk factors.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot